A
Alcista
Alcista · 25%ABBV
$230.51
Precio del escenario
$283.400
-0.085 (-0.03%)Al cierre
Loading chart…
- Máximo
- 291.400
- Apertura
- 288.280
- Precio medio ponderado por volumen
- 285.87
- Volumen
- 7.62M
- Capitalización
- 298.41B
- Mínimo
- 282.810
- Importe
- 2.18B
- EV/EBITDA, TTM
- 15.14
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Restasis. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its pipeline also includes zumilokibart and APG273.
Análisis de IA of AbbVie Inc. (ABBV)
ComprarAbbVie Inc is a good buy right now, primarily driven by its current price of $276.47, which is below the raised analyst price targets of $315 and $305. The company has shown strong revenue growth, with a gross margin of 74.74% in Q2 2026, and a solid year-to-date price increase of 20.57%. However, a notable risk is its high forward P/E ratio of 16.39, indicating potential overvaluation if growth does not meet expectations.
Recomendaciones de analistas (20)
-11.08% Potencial de caída
Comprar
10 Comprar
10 Mantener
0 Vender
Actual: 283.40
Mínimo
223.00
Promedio
252.00
Máximo
289.00
UBS
Neutral
$275
2026-10-09
UBS
2026-10-09
Precio objetivo
$275
Neutral
BofA
Comprar
$305
2026-10-09
BofA
2026-10-09
Precio objetivo
$305
Comprar
Cantor Fitzgerald
Sobreponderar
$290
2026-10-08
Cantor Fitzgerald
2026-10-08
Precio objetivo
$290
Sobreponderar
JPMorgan
Sobreponderar
$300
2026-10-08
JPMorgan
2026-10-08
Precio objetivo
$300
Sobreponderar
Morgan Stanley
Sobreponderar
$310
2026-10-07
Morgan Stanley
2026-10-07
Precio objetivo
$310
Sobreponderar
Métricas de valoración
El PER previsto actual de AbbVie Inc. (ABBV) es 16.39, frente a su media de 5 años de 14.22.
Escenarios de precio de Alphio AI para ABBV
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ABBV en cartera
Cronología de eventos
Noticias
6.510-15FoolInvestment Analysis: AbbVie vs. Pfizer
6.510-13FoolInvestment Comparison: AbbVie vs. Novo Nordisk
9.510-13CNBCJohnson & Johnson Reports Solid Quarter Amid Stock Slide
6.510-13FoolAbbVie vs. Eli Lilly: An Investor's Choice Analysis
9.510-11FoolAbbVie Dividend Yield Declines but Remains Attractive for Income Investors
Preguntas frecuentes sobre ABBV, respondidas por Alphio AI
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Restasis. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its pipeline also includes zumilokibart and APG273. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AbbVie Inc is a good buy right now, primarily driven by its current price of $276.47, which is below the raised analyst price targets of $315 and $305. The company has shown strong revenue growth, with a gross margin of 74.74% in Q2 2026, and a solid year-to-date price increase of 20.57%. However, a notable risk is its high forward P/E ratio of 16.39, indicating potential overvaluation if growth does not meet expectations.
20 analysts cover ABBV: 10 rate it Buy, 10 Hold and 0 Sell. The average price target is 252.00.
Comunidad
Más ↗
$ABBV is in a favorable rotation right now and is at new highs.
Mostrar más
5 Trade Ideas for Monday: AbbVie, Airbnb, Affirm, GE Aerospace and Walmart $ABBV $ABNB $AFRM $GE $WMT
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.